In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin
Introduction: The use of the psychedelic compound psilocybin in conjunction with psychotherapy has shown promising results in the treatment of psychiatric disorders, though the underlying mechanisms supporting these effects remain unclear. Psilocybin is a Schedule I …